Last Updated: September 28, 2026

Details for New Drug Application (NDA): 216457


✉ Email this page to a colleague

« Back to Dashboard


NDA 216457 describes APONVIE, which is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the APONVIE profile page.

The generic ingredient in APONVIE is aprepitant. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
Summary for 216457
Tradename:APONVIE
Applicant:Heron Theraps Inc
Ingredient:aprepitant
Patents:14
Pharmacology for NDA: 216457
Mechanism of ActionCytochrome P450 2C9 Inducers
Cytochrome P450 3A4 Inducers
Cytochrome P450 3A4 Inhibitors
Neurokinin 1 Antagonists
Suppliers and Packaging for NDA: 216457
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
APONVIE aprepitant EMULSION;INTRAVENOUS 216457 NDA Heron Therapeutics, Inc. 47426-401 47426-401-10 10 VIAL, GLASS in 1 CARTON (47426-401-10) / 4.4 mL in 1 VIAL, GLASS (47426-401-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:EMULSION;INTRAVENOUSStrength32MG/4.4ML (7.2MG/ML)
Approval Date:Sep 16, 2022TE:RLD:Yes
Patent:10,500,208Patent Expiration:Sep 18, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:10,624,850Patent Expiration:Sep 18, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Patent:10,953,018Patent Expiration:Sep 18, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links